2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Phase 3
Completed
- Conditions
- Postoperative Nausea and Vomiting
- Registration Number
- NCT00090246
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.
- Detailed Description
The duration of treatment is 4 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 922
Inclusion Criteria
- Patient is at least 18 years of age.
- Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery).
- Patient is scheduled to receive general anesthesia.
- Patient is scheduled to receive postoperative opioids.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Prevention of PONV in the 24 hours following end of surgery; Tolerability 24 hours
- Secondary Outcome Measures
Name Time Method